TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11421880

Group type: EXPERIMENTAL
Intervention: Omeprazole group (20 mg b.d. for 7 days + 14 days additional therapy with omeprazole 20 mg)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo group (7 days triple therapy + placebo for 14 days)
Number of subjects: 77
Study: 9408724

Group type: EXPERIMENTAL
Intervention: Informed consent practices
Number of subjects: 0
Study: 7970505

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 160 mg/day
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 480 mg/day
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 800 mg/day
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 1280 mg/day
Number of subjects: 342
Study: 3302193

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (retinyl palmitate 2000 IU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.9% saline solution (control)
Number of subjects: 40
Study: 31424173

Group type: EXPERIMENTAL
Intervention: Maxgraft
Number of subjects: 20

Group type: COMPARATOR
Intervention: Puros
Number of subjects: 20
Study: 29096949

Group type: EXPERIMENTAL
Intervention: Tight control management (using clinical symptoms and biomarkers)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Clinical management algorithm (symptom-driven decisions)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Tight control management
Number of subjects: 244

Group type: COMPARATOR
Intervention: Clinical management algorithm
Number of subjects: 244
Study: 25572620

Group type: EXPERIMENTAL
Intervention: Proactive quitline (counselor-initiated calls)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Reactive quitline (participant-initiated calls)
Number of subjects: 427
Study: 24640697

Group type: EXPERIMENTAL
Intervention: Chitomur (peptide bioregulator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21982309

Group type: EXPERIMENTAL
Intervention: MO.MA system (proximal protection)
Number of subjects: 53

Group type: COMPARATOR
Intervention: FilterWire EZ (distal protection)
Number of subjects: 53
Study: 18443259

Group type: EXPERIMENTAL
Intervention: Bothersome hot flushes reported at baseline
Number of subjects: 3167

Group type: EXPERIMENTAL
Intervention: Characteristics associated with baseline symptoms
Number of subjects: 3167

Group type: EXPERIMENTAL
Intervention: Persistence of symptoms after 3 years
Number of subjects: 3167

Group type: EXPERIMENTAL
Intervention: Characteristics associated with symptom persistence
Number of subjects: 3167
Study: 16805147

Group type: EXPERIMENTAL
Intervention: New bandage technology
Number of subjects: 15
Study: 14640928

Group type: EXPERIMENTAL
Intervention: Palonosetron (Aloxi)
Number of subjects: 0
Study: 11019429

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg (three times a day)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 688

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Orlistat (after switching from placebo)
Number of subjects: 688
Study: 8841227

Group type: EXPERIMENTAL
Intervention: Acyclovir prophylaxis during late pregnancy
Number of subjects: 1818

Group type: COMPARATOR
Intervention: Cesarean delivery for genital herpes lesions
Number of subjects: 1818

Group type: EXPERIMENTAL
Intervention: Acyclovir followed by cesarean delivery if lesions occur
Number of subjects: 1818
Study: 1584317

Group type: EXPERIMENTAL
Intervention: Calcium acetate (CA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 80
Study: 2867858

Group type: EXPERIMENTAL
Intervention: Norethisterone 1mg/ethinyl estradiol 35 micrograms (NET/EE)
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 150 micrograms/ethinyl estradiol 30 micrograms (LNG/EE)
Number of subjects: 847

Group type: COMPARATOR
Intervention: IUD (comparison group)
Number of subjects: 847
Study: 30986402

Group type: EXPERIMENTAL
Intervention: 32-inch diagonal video monitor
Number of subjects: 1795

Group type: COMPARATOR
Intervention: 19-inch diagonal video monitor
Number of subjects: 1795
Study: 29105871

Group type: EXPERIMENTAL
Intervention: Personalized and tailored letter from the GP and a personal invitation and appointment to attend a taster session providing information about SSS
Number of subjects: 4384

Group type: COMPARATOR
Intervention: Standard generic letter from the GP advertising SSS
Number of subjects: 4384
Study: 27130912

Group type: EXPERIMENTAL
Intervention: Mesh group - lightweight monofilament mesh (<50g/m(2)) inserted in a sublay location during end-colostomy creation.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional stoma formation (control group).
Number of subjects: 200
Study: 23620494

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (ECC1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concentric exercise (CONC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repeated eccentric exercise (ECC2)
Number of subjects: 0
Study: 23134097

Group type: EXPERIMENTAL
Intervention: Post-discharge warfarin management service with pharmacist education during two or three home visits.
Number of subjects: 268

Group type: COMPARATOR
Intervention: Usual community-based post-discharge care.
Number of subjects: 268
Study: 20607877

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EDA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Patient controlled analgesia (PCA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 24
Study: 18389448

Group type: EXPERIMENTAL
Intervention: Guide-wire cannulation
Number of subjects: 413

Group type: COMPARATOR
Intervention: Contrast cannulation
Number of subjects: 413
Study: 15558237

Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients
Number of subjects: 145

Group type: COMPARATOR
Intervention: Non-diabetic control subjects
Number of subjects: 145
Study: 14602503

Group type: EXPERIMENTAL
Intervention: EGb 761 (240 mg, t.i.d.)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 10191137

Group type: EXPERIMENTAL
Intervention: Melatonin 2.5 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 8564107

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1.5 mg inhaled daily for 8 weeks
Number of subjects: 17
Study: 8664173

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (Group A: smokers vs nonsmokers)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (Group B: smokers vs nonsmokers)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (Group A and B: smokers vs nonsmokers)
Number of subjects: 289
Study: 3537268

Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline sulfate (0.25 mg) administered to 43/85 (50.5%) of ECV candidates
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Successful ECV
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Cesarean section
Number of subjects: 85

Group type: COMPARATOR
Intervention: ECV failure
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Meconium aspiration
Number of subjects: 85
Study: 30440139

Group type: EXPERIMENTAL
Intervention: Mesogastrium excision above the pancreas by the right approach (n=78)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Mesogastrium excision above the pancreas by the left approach (n=76)
Number of subjects: 154
Study: 27739067

Group type: EXPERIMENTAL
Intervention: CAREPATH intervention (depression care management)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 755
Study: 24183344

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich fibrin glue (PRFG)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (non-PRFG approach)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: PRFG in PS-matched cohort
Number of subjects: 145
Study: 23321171

Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 186

Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 186
Study: 20865240

Group type: EXPERIMENTAL
Intervention: Sulodexide (200 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 18000175

Group type: EXPERIMENTAL
Intervention: Risk score based on log‐BMI, age, log‐fasting C‐peptide, and postchallenge glucose and C‐peptide sums from 2‐h oral glucose tolerance tests (OGTTs)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Risk score additionally dependent on a decreased first‐phase insulin response variable from intravenous glucose tolerance tests (IVGTTs)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Change in the type 1 diabetes risk score from baseline to 1 year
Number of subjects: 670
Study: 15871851

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10mg/day)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Pravastatin (20mg/day)
Number of subjects: 86
Study: 12832364

Group type: COMPARATOR
Intervention: Allogeneic SCT (n = 23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Autologous SCT (n = 22)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Allo-SCT with cGVHD (n = 13)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Combined group of SCT patients (allo + auto)
Number of subjects: 45
Study: 10208315

Group type: EXPERIMENTAL
Intervention: R(+)‐nicotine vapor (40, 80, 120, 160 ng/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S(‐)‐nicotine vapor (40, 80, 120, 160 ng/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olfactory detection threshold for 'odorous' sensation (not specified)
Number of subjects: 0
Study: 8023964

Group type: EXPERIMENTAL
Intervention: Felodipine + Aldosterone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Aldosterone alone
Number of subjects: 12
Study: 2493302

Group type: EXPERIMENTAL
Intervention: Interferon alfa 5 megaunits (MU) daily for one week, reducing to 5 MU thrice weekly for seven weeks, then 3 MU thrice weekly for eight weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 14
Study: 769484

Group type: EXPERIMENTAL
Intervention: Mepiprazol (EMD 16.923)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 8
Study: 30818406

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring
Number of subjects: 40

Group type: COMPARATOR
Intervention: Blinded continuous glucose monitoring
Number of subjects: 40
Study: 29241306

Group type: EXPERIMENTAL
Intervention: ALC intake + SDP
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PLA intake + SDP
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SDP conditions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined and isolated ALC intake and one night of SDP
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined effects of ALC intake and SDP
Number of subjects: 10
Study: 25138128

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 140

Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 140
Study: 23246389

Group type: EXPERIMENTAL
Intervention: Sites with 1 to 10 participants
Number of subjects: 4133

Group type: EXPERIMENTAL
Intervention: Sites with 11 to 30 participants
Number of subjects: 4133

Group type: COMPARATOR
Intervention: Sites with >30 participants
Number of subjects: 4133

Group type: EXPERIMENTAL
Intervention: Sites with 1 to 10 participants (adjusted for risk factors)
Number of subjects: 4133

Group type: EXPERIMENTAL
Intervention: Sites with 11 to 30 participants (adjusted for risk factors)
Number of subjects: 4133

Group type: EXPERIMENTAL
Intervention: Protocol completion rates
Number of subjects: 4133
Study: 21376564

Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil patient-controlled analgesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epidural ropivacaine/sufentanil
Number of subjects: 20
Study: 19051552

Group type: EXPERIMENTAL
Intervention: Procera all-ceramic copings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cerec-in-lab copings
Number of subjects: 0

Group type: COMPARATOR
Intervention: IPS Empress 2 copings
Number of subjects: 0
Study: 16834525

Group type: EXPERIMENTAL
Intervention: Drug laboratory monitoring alerts within the CPOE system
Number of subjects: 207

Group type: COMPARATOR
Intervention: No alerts (Control)
Number of subjects: 207
Study: 12767083

Group type: COMPARATOR
Intervention: FAC (5-fluorouracil, doxorubicin, and cyclophosphamide)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: FAC + MV (methotrexate and vinblastine)
Number of subjects: 789

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: FAC + MV (in Group 2)
Number of subjects: 789
Study: 10799352

Group type: EXPERIMENTAL
Intervention: Kamillosan(R) cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% hydrocortisone cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle cream (placebo)
Number of subjects: 0
Study: 9277559

Group type: EXPERIMENTAL
Intervention: High calcium intake (1,800 mg/day)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control calcium intake (800 mg/day)
Number of subjects: 5
Study: 8426248

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 2442610

Group type: EXPERIMENTAL
Intervention: Bacterial polysaccharide immune globulin (BPIG) 0.5 ml/kg body weight, administered intramuscularly at 2, 6, and 10 months of age.
Number of subjects: 703

Group type: COMPARATOR
Intervention: Saline (placebo) 0.5 ml/kg body weight, administered intramuscularly at 2, 6, and 10 months of age.
Number of subjects: 703
Study: 29650803

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control (Self-Monitoring of Blood Glucose)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Lifetime analysis of CGM
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Extended sensor use from 7 to 10 days
Number of subjects: 158
Study: 26469356

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus casei Shirota (LcS), administered twice daily for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo, administered twice daily for 8 weeks
Number of subjects: 80
Study: 25503546

Group type: EXPERIMENTAL
Intervention: a-NIHSS item profiles
Number of subjects: 10271

Group type: EXPERIMENTAL
Intervention: b-NIHSS item profiles
Number of subjects: 10271
Study: 23053462

Group type: EXPERIMENTAL
Intervention: Trachway intubating stylet
Number of subjects: 38

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 38
Study: 20348164

Group type: EXPERIMENTAL
Intervention: Modified tandem traction bow appliance (modified TTBA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Modified tandem traction bow appliance (modified TTBA) - Early treatment group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Modified tandem traction bow appliance (modified TTBA) - Late treatment group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (observed without treatment for 8 months)
Number of subjects: 45
Study: 18227988

Group type: EXPERIMENTAL
Intervention: 3-point AUC (AUCp) for vitamin A-fortified skim milk
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 3-point AUC (AUCp) for whole milk
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 3-point AUC (AUCp)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 7-point AUC (AUCc)
Number of subjects: 19
Study: 16598414

Group type: EXPERIMENTAL
Intervention: Simplified POPQ exam
Number of subjects: 48
Study: 14711187

Group type: EXPERIMENTAL
Intervention: Electrode pad position over the right lower sternal border-left infrascapular area (AP group, n = 39)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Electrode pad position over the ventricular apex-right infraclavicular area (AL group, n = 31)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All patients as a group
Number of subjects: 70
Study: 11778530

Group type: EXPERIMENTAL
Intervention: Local chemotherapy by fibrobronchoscopy with carboplatin 300 mg combined with intravenous chemotherapy (carboplatin and etoposide regimen)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous chemotherapy with routine carboplatin and etoposide regimen
Number of subjects: 40
Study: 8668877

Group type: EXPERIMENTAL
Intervention: Injectable gold
Number of subjects: 44

Group type: COMPARATOR
Intervention: Auranofin
Number of subjects: 44
Study: 1510170

Group type: EXPERIMENTAL
Intervention: Head-up tilt without neck suction
Number of subjects: 8

Group type: COMPARATOR
Intervention: Head-up tilt with neck suction (23 +/- 1 mmHg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Neck suction
Number of subjects: 8
Study: 7056070

Group type: EXPERIMENTAL
Intervention: Drionic device treatment for hyperhidrosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (baseline sweat print of 1)
Number of subjects: 0
Study: 29501349

Group type: EXPERIMENTAL
Intervention: Anodal tDCS on left M1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 10
Study: 29087231

Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26894651

Group type: EXPERIMENTAL
Intervention: Ciclosporin
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 381

Group type: COMPARATOR
Intervention: Control (Donor-recipient Cytomegalovirus mismatch)
Number of subjects: 381
Study: 24292257

Group type: EXPERIMENTAL
Intervention: NG/NJT placement
Number of subjects: 270

Group type: COMPARATOR
Intervention: no-NG/NJT placement
Number of subjects: 270
Study: 22123358

Group type: EXPERIMENTAL
Intervention: Tolvaptan (TLV) 30 mg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Furosemide (FURO) 80 mg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tolvaptan (TLV) 30 mg and Furosemide (FURO) 80 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 19770596

Group type: EXPERIMENTAL
Intervention: Supervised neck/shoulder exercise regimen
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no exercise regimen)
Number of subjects: 68
Study: 16847014

Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mini incision open donor nephrectomy
Number of subjects: 100
Study: 14967419

Group type: EXPERIMENTAL
Intervention: Iseganan oral solution plus standard-of-care oral hygiene (SOC)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Placebo plus standard-of-care oral hygiene (SOC)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Standard-of-care oral hygiene (SOC) alone
Number of subjects: 545
Study: 11055776

Group type: EXPERIMENTAL
Intervention: Mercurius solubilis
Number of subjects: 104
Study: 9381995

Group type: EXPERIMENTAL
Intervention: High-intensity strength training
Number of subjects: 38
Study: 8258082

Group type: EXPERIMENTAL
Intervention: Telephone interview (TEL)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard consultation (STD)
Number of subjects: 1000
Study: 3723570

Group type: EXPERIMENTAL
Intervention: Critiques from preceptors
Number of subjects: 105

Group type: COMPARATOR
Intervention: Self-guided critiques using a written checklist
Number of subjects: 105

Group type: COMPARATOR
Intervention: No critiques (control group)
Number of subjects: 105
Study: 31042402

Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 11
Study: 28602159

Group type: EXPERIMENTAL
Intervention: Larger wine glass (370 ml)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Smaller wine glass (250 ml)
Number of subjects: 166
Study: 25881226

Group type: EXPERIMENTAL
Intervention: Pharmacist based intervention including phone‐based pharmacist intervention, pharmacist‐physician collaboration, patient education, and a CKD registry
Number of subjects: 2199

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: Pharmacist based intervention
Number of subjects: 2199
Study: 23703604

Group type: EXPERIMENTAL
Intervention: Medication self-management education program (5 sessions including verbal education, 1:1 consultation, practice in medication self-management, and discussion)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study: 21726257

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg/day) plus aspirin (100 mg/day)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Rabeprazole (20 mg/day) plus clopidogrel (75 mg/day)
Number of subjects: 218
Study: 18826422

Group type: EXPERIMENTAL
Intervention: Dual task performance in patients with aMCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual task performance in elderly controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PET activation in left inferior frontal region during dual task performance in patients with aMCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: PET activation in left inferior frontal region during dual task performance in elderly controls
Number of subjects: 0
Study: 16393593

Group type: EXPERIMENTAL
Intervention: 595 nm cryogen‐cooled pulsed dye laser treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (untreated portion of the scar)
Number of subjects: 16
Study: 15459593

Group type: EXPERIMENTAL
Intervention: Diltiazem ER tablets (240 mg titrated to 360 mg and to 540 mg)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Ramipril (5 mg titrated to 10 mg and to 20 mg)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Diltiazem ER tablets
Number of subjects: 261

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 261
Study: 11263782

Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS) with or without cyclophosphamide (CYC)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Corticosteroids (CS) alone
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Hepatitis B virus (HBV)‐related PAN
Number of subjects: 278

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 278
Study: 9378194

Group type: EXPERIMENTAL
Intervention: DDIR pacing mode
Number of subjects: 79

Group type: COMPARATOR
Intervention: DDI pacing mode
Number of subjects: 79

Group type: COMPARATOR
Intervention: DDI + DDIR pacing modes
Number of subjects: 79
Study: 8354536

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg) + Propantheline bromide (15 mg) at bedtime
Number of subjects: 161

Group type: COMPARATOR
Intervention: Ranitidine (300 mg) at bedtime
Number of subjects: 161